Prognostic Value of Sarcopenia in Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil

Malik, M.; Michalak, Maciej; Radecka, Barbara; Gełej, M.; Jackowska, Aleksandra; Filipczyk−Cisarż, Emilia; Hetman, Katarzyna; Foszczyńska-Kłoda, Małgorzata; Kania-Zembaczyńska, Beata; Mańka, D.; Orlikowska, Marlena; Bodnar, Lubomir

doi:10.3390/jcm10215107

Cited by 6 publications

(6 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Table 1 presents the baseline characteristics of the included studies. Among the studies published between 20 16 and 2022, 8 studies [ 27 – 29 , 37 , 40 , 42 , 45 , 46 ] were from Asia, 7 studies [ 39 , 41 , 43 , 44 , 47 – 49 ] were from Europe and a separate study [ 38 ] from Brazil. All of the studies were retrospective cohort, and 68.75% of the included studies (11/16) were of high quality with an NOS score of ≥ 7).…”

Section: Resultsmentioning

confidence: 99%

“…During this process, we excluded 688 irrelevant citations and 68 potentially relevant studies were selected for full-text review. Due to non-population-based cohorts, reviews, meta-analyses or no outcome data reported, 16 studies [27][28][29][37][38][39][40][41][42][43][44][45][46][47][48][49] involving 1,675 participants satisfied the inclusion criteria and were eligible to be included in the final metaanalysis (Fig. 1).…”

Section: Literature Search and Study Characteristicsmentioning

confidence: 99%

See 1 more Smart Citation

Sarcopenia as a risk factor of progression-free survival in patients with metastases: a systematic review and meta-analysis

et al. 2023

View full text Add to dashboard Cite

Background Metastasis of cancer causes more than 90% of cancer deaths and is severely damaging to human health. In recent years, several studies have linked sarcopenia to shorter survival in patients with metastatic cancer. Several predictive models exist to predict mortality in patients with metastatic cancer, but have reported limited accuracy. Methods We systematically searched Medline, EMBASE, and the Cochrane Library for articles published on or before October 14, 2022. Pooled Hazard Ratio (HR) estimates with 95% confidence intervals (CIs) were calculated using a random effects model. The primary outcome was an increased risk of death or tumor progression in patients with metastatic cancer, which is expressed as progression-free survival (PFS). In addition, we performed subgroup analyses and leave-one-out sensitivity analyses to explore the main sources of heterogeneity and the stability of the results. Results Sixteen retrospective cohort studies with 1,675 patients were included in the 888 papers screened. The results showed that sarcopenia was associated with lower progression-free survival (HR = 1.56, 95% CI = 1.19–2.03, I2 = 76.3%, P < 0.001). This result was further confirmed by trim-and-fill procedures and leave-one-out sensitivity analysis. Conclusions This study suggests that sarcopenia may be a risk factor for reduced progression-free survival in patients with metastatic cancer. Further studies are still needed to explain the reason for this high heterogeneity in outcome. Trial registration CRD42022325910.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Literature Search and Study Characteristicsmentioning

confidence: 99%

Sarcopenia as a risk factor of progression-free survival in patients with metastases: a systematic review and meta-analysis

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Seven designs defined endpoint CT timing using a set number of chemotherapy cycles, ranging from one to six cycles; however, the length of one cycle was not often reported 23,34,40,50,51,54,55 . Ten designs specified a treatment or disease milestone as the endpoint, including first reassessment, 30,31,43,53 progression 18,44,49,52 and last CT 36,46 . Non‐specific descriptors for the endpoint, such as ‘during treatment’ or ‘after treatment’, were applied in five designs 24,27,35,38,48 .…”

Section: Study Design: Scan Timing and Intervalsmentioning

confidence: 99%

“…The relationship between SM change and chemotherapy toxicity was explored in eight studies. Of these, five publications compared the incidence of treatment toxicities between ‘SM losers’ and ‘SM non‐losers’ (i.e., univariable), 25,27,31,32,40 and three included SM loss in multivariable logistic regression to predict odds of toxicity 22,29,50 . The relationship between SM loss and changes in health‐related quality of life or physical function was explored in four studies 19,39,40,59 …”

Section: Application Of Skeletal Muscle and Adipose Change To Clinica...mentioning

confidence: 99%

Call for standardization in assessment and reporting of muscle and adipose change using computed tomography analysis in oncology: A scoping review

Klassen,

Mazurak,

Thorlakson

et al. 2023

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

Investigators are increasingly measuring skeletal muscle (SM) and adipose tissue (AT) change during cancer treatment to understand impact on patient outcomes. Recent meta‐analyses have reported high heterogeneity in this literature, representing uncertainty in the resulting estimates. Using the setting of palliative‐intent chemotherapy as an exemplar, we aimed to systematically summarize the sources of variability among studies evaluating SM and AT change during cancer treatment and propose standards for future studies to enable reliable meta‐analysis. Studies that measured computed tomography‐defined SM and/or AT change in adult patients during palliative‐intent chemotherapy for solid tumours were included, with no date or geographical limiters. Of 2496 publications screened by abstract/title, 83 were reviewed in full text and 38 included for extraction, representing 34 unique cohorts across 8 tumour sites. The timing of baseline measurement was frequently defined as prior to treatment, while endpoint timing ranged from 6 weeks after treatment start to time of progression. Fewer than 50% specified the actual time interval between measurements. Measurement error was infrequently discussed (8/34). A single metric (cm2/m2, cm2 or %) was used to describe SM change in 18/34 cohorts, while multiple metrics were presented for 10/34 and no descriptive metrics for 6/34. AT change metrics and sex‐specific reporting were available for 10/34 cohorts. Associations between SM loss and overall survival were evaluated in 24 publications, with classification of SM loss ranging from any loss to >14% loss over variable time intervals. Age and sex were the most common covariates, with disease response in 50% of models. Despite a wealth of data and effort, heterogeneity in study design, reporting and statistical analysis hinders evidence synthesis regarding the severity and outcomes of SM and AT change during cancer treatment. Proposed standards for study design include selection of homogenous cohorts, clear definition of baseline/endpoint timing and attention to measurement error. Standard reporting should include baseline SM and AT by sex, actual scan interval, SM and AT change using multiple metrics and visualization of the range of change observed. Reporting by sex would advance understanding of sexual dimorphism in SM and AT change. Evaluating the impact of tissue change on outcomes requires adjustment for relevant covariates and concurrent disease response. Adoption of these standards by researchers and publishers would alter the current paradigm to enable meta‐analysis of future studies and move the field towards meaningful application of SM and AT change to clinical care.

show abstract

“…In addition to oncological factors and treatment factors, the outcomes of cancer treatment are greatly influenced by host factors, such as the nutritional status, immune status, systemic inflammation, and intestinal flora (1)(2)(3)(4)(5)(6). Malnutrition has been reported to be associated with shorter survival time after curative surgery and worse chemotherapeutic efficacy in patients with various gastrointestinal malignancies (7)(8)(9)(10)(11). In our previous study, the prognostic nutritional index (PNI), which was calculated based on the serum albumin concentration and peripheral lymphocyte count, was found to be correlated with the chemotherapeutic outcomes in patients with unresectable metastatic colorectal cancer (12).…”

mentioning

confidence: 99%

Impact of Preoperative Nutritional Status on Long-term Survival in Patients With Stage I-III Colorectal Cancer

Shibutani¹,

Kashiwagi²,

Fukuoka³

et al. 2023

In Vivo

View full text Add to dashboard Cite

Background/Aim: In addition to oncological and treatment factors, the outcomes of cancer treatment are greatly influenced by host factors, such as the nutritional status. The aim of this study was to evaluate the association between the preoperative nutritional status and the prognosis of colorectal cancer patients using three nutritional indices. Patients and Methods: The target cohort consisted of 529 patients with stage I-III colorectal cancer, who underwent curative surgery between January 2015 and December 2019. The nutritional indices were calculated according to the equations that follow. Prognostic nutritional index (PNI)=10×serum albumin concentration (g/dl) +0.005×peripheral lymphocyte count (/μl). Nutritional risk index (NRI)=15.19×serum albumin concentration (g/dl)+41.7×present weight/usual weight. Geriatric nutritional risk index (GNRI)=14.89×serum albumin concentration (g/dl)+41.7×present weight/ideal weight. Ideal weight was calculated as follows: height(cm)-100-[(height(cm)-150)/4] for men and height(cm)-100-[(height(cm)-150)/2.5] for women. Results: In common with all nutritional indices (PNI, NRI and GNRI), the low-nutritional index group had significantly lower relapse-free and overall survival rates than the high-nutritional index group. Furthermore, a subgroup analysis according to the NRI showed the association of the NRI with the patient prognosis for each stage. Conclusion: The preoperative nutritional status may have a close relationship with the prognosis in patients who receive curative surgery for colorectal cancer. Patients and MethodsPatients. The target cohort consisted of 529 patients with stage I-III colorectal cancer, who underwent curative surgery at the

show abstract

Prognostic Value of Sarcopenia in Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil

Cited by 6 publications

References 24 publications

Sarcopenia as a risk factor of progression-free survival in patients with metastases: a systematic review and meta-analysis

Sarcopenia as a risk factor of progression-free survival in patients with metastases: a systematic review and meta-analysis

Call for standardization in assessment and reporting of muscle and adipose change using computed tomography analysis in oncology: A scoping review

Impact of Preoperative Nutritional Status on Long-term Survival in Patients With Stage I-III Colorectal Cancer

Contact Info

Product

Resources

About